Premium
Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice
Author(s) -
Oostveen A.M.,
Jong E.M.G.J.,
Donders A.R.T.,
Kerkhof P.C.M.,
Seyger M.M.B.
Publication year - 2015
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.12789
Subject(s) - medicine , scalp , betamethasone dipropionate , psoriasis , quality of life (healthcare) , betamethasone , dermatology , clinical practice , alopecia areata , observational study , physical therapy , nursing
Background Evidence on efficacy and safety of topical treatments for paediatric scalp psoriasis is lacking. Objective This study aims to evaluate the effectiveness and safety of calcipotriene/betamethasone dipropionate scalp formulation for paediatric scalp psoriasis in daily clinical practice. The influence of this formulation on the quality of life (QoL) was assessed as well. Methods Data of children treated with the scalp formulation were extracted from a prospective observational daily clinical practice registry of children with psoriasis, called Child‐Continuous Assessment of Psoriasis Treatment Use Registry. Severity was expressed by Psoriasis Scalp Severity Index ( PSSI ) and the impact on the QoL was reflected by the validated Children's Scalpdex in Psoriasis ( CSP ). Results Eighty‐four treatment episodes were analysed. Significant improvements of PSSI score (18.7 ± 11.8 to 12.7 ± 9.4) were demonstrated in the first 12 weeks and this result was well maintained during 48 weeks of follow‐up. Three patients (4.1%) developed striae of the skin (arms, trunk and legs), which are possibly related to the scalp formulation. CSP scores (79.0–46.3) declined significantly after 3 months. Conclusion In a daily clinical practice cohort of children with scalp psoriasis, calcipotriene/betamethasone dipropionate scalp formulation was effective with a 32.1% improvement of PSSI at week 12 and a maintenance of this effect until 48 weeks of follow‐up, in combination with improvement of QoL.